Literature DB >> 16931584

Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1.

Tahar van der Straaten1, Dinemarie Kweekel, Marco Tiller, Judith Bogaartz, Henk-Jan Guchelaar.   

Abstract

DNA repair enzymes play a pivotal role in platinum-based chemotherapy. Within the gene encoding for the base excision repair enzyme XRCC1, several nonsynonymous polymorphisms have been identified. It has been shown that the Arg399Gln single-nucleotide polymorphism results in a polymorphic enzyme that is less capable of initiating DNA repair. We developed a multiplex pyrosequence assay to simultaneously detect two nonsynonymous polymorphisms within the XRCC1 gene. Both of these polymorphisms resulted in amino acid changes: G/A in codon 399 changes Arg into Gln, and deletion of A in the second position of codon 576 results in a stopcodon. We established the frequency of these mutations in 270 patients suffering from colorectal cancer. Allele frequencies of G in second position of codon 399 and A in the second position codon 576 are 61.1 and 99.6%, respectively, in these patients. This fast and reliable method allows for simultaneous detection of the infrequent mutant C or CT alleles instead of the A deletion at codon 576. The method may be used in pharmacogenetic studies of platinum-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931584      PMCID: PMC1867628          DOI: 10.2353/jmoldx.2006.060018

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  17 in total

1.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

Authors:  D J Park; J Stoehlmacher; W Zhang; D D Tsao-Wei; S Groshen; H J Lenz
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

Authors:  J Stoehlmacher; V Ghaderi; S Iobal; S Groshen; D Tsao-Wei; D Park; H J Lenz
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

Review 3.  Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

Authors:  S Shall; G de Murcia
Journal:  Mutat Res       Date:  2000-06-30       Impact factor: 2.433

Review 4.  Modulation of DNA repair processes by arsenic and selenium compounds.

Authors:  A Hartwig; H Blessing; T Schwerdtle; I Walter
Journal:  Toxicology       Date:  2003-11-15       Impact factor: 4.221

Review 5.  The impact of pharmacogenomics on gastrointestinal cancer therapy.

Authors:  Thomas Seufferlein; Bernhard O Boehm
Journal:  Pharmacogenomics       Date:  2002-09       Impact factor: 2.533

Review 6.  The PARP superfamily.

Authors:  Jean-Christophe Amé; Catherine Spenlehauer; Gilbert de Murcia
Journal:  Bioessays       Date:  2004-08       Impact factor: 4.345

7.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

Authors:  Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Wei Zhou; Li Su; John C Wain; Thomas J Lynch; Donna S Neuberg; David C Christiani
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

Review 8.  [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].

Authors:  J B Tuynman; J B Hulscher; E Ph Steller; J J van Lanschot; D J Richel
Journal:  Ned Tijdschr Geneeskd       Date:  2003-11-08

9.  Spatial and temporal cellular responses to single-strand breaks in human cells.

Authors:  Satoshi Okano; Li Lan; Keith W Caldecott; Toshio Mori; Akira Yasui
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

10.  A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.

Authors:  Sherif F El-Khamisy; Mitsuko Masutani; Hiroshi Suzuki; Keith W Caldecott
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

View more
  5 in total

1.  Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools.

Authors:  Emelyne Dejeux; Virginie Audard; Catherine Cavard; Ivo Glynne Gut; Benoit Terris; Jörg Tost
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

2.  Integrative gene set analysis: application to platinum pharmacogenomics.

Authors:  Brooke L Fridley; Ryan Abo; Xiang-Lin Tan; Gregory D Jenkins; Anthony Batzler; Ann M Moyer; Joanna M Biernacka; Liewei Wang
Journal:  OMICS       Date:  2013-11-07

3.  Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.

Authors:  Jatinder Kaur Lamba; Brooke L Fridley; Taraswi M Ghosh; Qing Yu; Gaurav Mehta; Pankaj Gupta
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

4.  Platinum pathway.

Authors:  Sharon Marsh; Howard McLeod; Eileen Dolan; Sunita J Shukla; Cara A Rabik; Li Gong; Tina Hernandez-Boussard; Xing Jian Lou; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2009-07       Impact factor: 2.089

5.  Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.

Authors:  D M Kweekel; N F Antonini; J W R Nortier; C J A Punt; H Gelderblom; H-J Guchelaar
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.